Research Analysts Issue Forecasts for AVTX Q1 Earnings

Avalo Therapeutics, Inc. (NASDAQ:AVTX) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Avalo Therapeutics in a research note issued on Thursday, March 20th. HC Wainwright analyst E. White expects that the company will earn ($1.06) per share for the quarter. HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Avalo Therapeutics’ current full-year earnings is ($19.07) per share. HC Wainwright also issued estimates for Avalo Therapeutics’ Q2 2025 earnings at ($1.09) EPS and Q3 2025 earnings at ($1.13) EPS.

Several other equities research analysts also recently commented on the stock. Piper Sandler began coverage on shares of Avalo Therapeutics in a report on Friday, February 28th. They set an “overweight” rating and a $48.00 price objective on the stock. BTIG Research began coverage on shares of Avalo Therapeutics in a research note on Thursday, December 19th. They set a “buy” rating and a $40.00 price target on the stock. Finally, Wedbush reiterated an “outperform” rating and issued a $18.00 price objective on shares of Avalo Therapeutics in a research note on Thursday, March 20th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $35.33.

Avalo Therapeutics Trading Down 0.4 %

AVTX stock opened at $7.63 on Monday. The stock has a fifty day moving average of $7.47 and a 200-day moving average of $9.13. Avalo Therapeutics has a fifty-two week low of $4.60 and a fifty-two week high of $34.46.

Institutional Investors Weigh In On Avalo Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. RA Capital Management L.P. bought a new stake in Avalo Therapeutics during the 3rd quarter worth approximately $9,186,000. Ikarian Capital LLC increased its holdings in shares of Avalo Therapeutics by 1,673.0% in the third quarter. Ikarian Capital LLC now owns 970,359 shares of the company’s stock worth $9,218,000 after purchasing an additional 915,629 shares during the period. Affinity Asset Advisors LLC increased its holdings in shares of Avalo Therapeutics by 1,123.9% in the fourth quarter. Affinity Asset Advisors LLC now owns 550,765 shares of the company’s stock worth $4,092,000 after purchasing an additional 505,765 shares during the period. Velan Capital Investment Management LP purchased a new stake in shares of Avalo Therapeutics in the fourth quarter worth $817,000. Finally, Geode Capital Management LLC boosted its stake in Avalo Therapeutics by 937.0% during the fourth quarter. Geode Capital Management LLC now owns 104,853 shares of the company’s stock valued at $779,000 after buying an additional 94,742 shares during the period. 87.06% of the stock is owned by hedge funds and other institutional investors.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.